Hepatitis A immunoglobulin


Concise Prescribing Info
Indications/Uses
Passive immunisation against hepatitis A infection.
Dosage/Direction for Use
Adult : IM Pre-exposure: For travel <3 mth: 0.02 mL/kg as a single dose; for travel >3 mth: 0.06 mL/kg/dose, may repeat every 5 mth if continued protection is required. Post-exposure (w/in 2 mth of exposure): 0.02 mL/kg as a single dose.
Dosage Details
Intramuscular
Passive immunisation against hepatitis A infection
Adult: Pre-exposure for travellers to endemic areas: For travel <3 mth, 0.02 ml/kg as a single dose; for travel >3 mth (each dose offers protection for 3-5 mth), 0.06 ml/kg/dose, may repeat every 5 mth if continued protection is required. Post-exposure (within 2 mth of exposure): 0.02 ml/kg as a single dose. Dose to be given by IM inj, into either the deltoid or gluteal muscles.
Contraindications
Patients with IgA deficiency.
Special Precautions
Pregnancy and lactation.
Adverse Reactions
Pain and erythema at inj site. Headache, malaise.
Drug Interactions
May reduce the immunogenicity of live vaccines when used concurrently.
Action
Description: Hepatitis A immunoglobulin is used for passive immunisation against hepatitis A infection. It provides short-term (1-2 mth) protection from hepatitis A. It is a sterile preparation of concentrated antibodies (immunoglobulins) made from pooled human plasma. It is usually used in persons planning to travel within 2-4 wk and who require immediate protection or for those with contraindications for vaccination.
Storage
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Hepatitis A immunoglobulin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in